DNAVision to offer Ipsogen's gene profiling tests for breast cancer:
This article was originally published in Clinica
Executive Summary
Marseille, France-based Ipsogen has secured a contract to supply DNAVision, a Belgium-based provider of pharmacogenomic testing services, with gene profiling tests for breast cancer. The agreement will see Ipsogen's tests being offered to institutions and patients in a CLIA/ISO17025 certified environment, "at the level of quality of quantitative PCR, the industry standard," said Ipsogen. The agreement comes shortly after the company gained a licence to Affymetrix' microarray technology, which is incorporated in Ipsogen's molecular diagnostic products.